Skip to main content

Table 1 Summary statistics on plasma concentrations of AZD3778 (μmol/L).

From: Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis

Variable

n

Gmean

CV

Min

Median

Max

Day 1, post-dose

34

5.49

38.5

2.45

5.83

10.40

Day 8, pre-dose

24

2.51

98.0

0.29

3.41

6.27

Day 8, post dose

34

7.77

44.4

3.14

7.95

20.10

Day 9, pre-dose

26

2.21

106.4

0.32

2.79

8.13

Day 9, post dose

34

7.55

36.0

3.15

7.51

15.60

Day 10, pre-dose

34

2.53

71.0

0.28

2.95

7.84

Day 10, post dose

34

7.19

36.5

3.29

7.34

13.50

  1. Plasma levels of AZD3778 were stable during the last three days of the treatment series.